Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 18/20 | 0.56 |
| ▸ | CYBB | P04839 | 2/20 | 0.45 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3611116 | 0.83 | NOX4 (0.67) | NOX4CYBB | |
| SCHEMBL3606000 | 0.80 | NOX4 (0.71) | NOX4 | |
| SCHEMBL3610001 | 0.78 | NOX4 (0.49) | NOX4CYBBNOX1NOX5 | |
| SCHEMBL1302610 | 0.77 | NOX4 (0.81) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL2213626 | 0.76 | NOX4 (0.59) | NOX4 | |
| SCHEMBL1303271 | 0.76 | NOX4 (0.68) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL1302720 | 0.76 | NOX4 (0.56) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL1303115 | 0.76 | NOX4 (0.66) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL1303316 | 0.75 | NOX4 (0.66) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL17131858 | 0.75 | NOX4 (0.74) | NOX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073919-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-07-07 | — | — | US | claimed |
| EP-2545918-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-08-06 | — | — | EP | claimed |
| US-20130123256-A1 | Pyrazolo Pyridine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2013-05-16 | — | — | US | claimed |
| US-8389518-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-03-05 | — | — | US | claimed |
| EP-2545918-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-01-16 | — | — | EP | claimed |
| EP-2139477-B1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2012-12-12 | — | — | EP | claimed |
| US-20100048560-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-02-25 | — | — | US | claimed |
| US-9073919-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073919-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073919-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-07-07 | — | — | US | disclosed |
| EP-2545918-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-20130123256-A1 | Pyrazolo Pyridine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2013-05-16 | — | — | US | disclosed |
| US-20130123256-A1 | Pyrazolo Pyridine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2013-05-16 | — | — | US | disclosed |
| US-8389518-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-03-05 | — | — | US | disclosed |
| US-8389518-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-03-05 | — | — | US | disclosed |
| EP-2545918-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-01-16 | — | — | EP | disclosed |
| EP-2139477-B1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-20100048560-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048560-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048560-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048560-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885CYBB 3/4885NOX1 1/4885 |
| US-20130123256-A1 | Pyrazolo Pyridine Derivatives as NADPH Oxidase Inhibitors | NOX1, NOX4, CYBB | NOX4 2/4885CYBB 3/4885NOX1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.